Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial

Figures & data

Figure 1 All cause mortality in the COMET trial. Copyright © 2003. Reproduced with permission from Poole-Wilson PA, Swedberg K, Cleland JG, et al. 2003. Comparison of carvedilol and metoprolol on clinical outcomes in patients withchronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet, 362:7–13.

Abbreviations: COMET, The Carvedilol Or Metoprolol European Trial.

Figure 2 Heart rate during treatment in the COMET trial. Copyright © 2003. Reproduced with permission from Poole-Wilson PA, Swedberg K, Cleland JG, etal. 2003. Comparison of carvedilol and metoprolol on clinical outcomes inpatients with chronic heart failure in the Carvedilol Or Metoprolol EuropeanTrial (COMET): randomised controlled trial. Lancet, 362:7–13.

Abbreviations: COMET, The Carvedilol Or Metoprolol European Trial. *p=0.0022, †p=0.034, ‡p=0.0040.

Table 1 The possible effect of the adrenoreceptors in the progression of heart failure. Copyright © 2004. Reproduced with permission from Metra M, Cas LD, di Lenarda A, et al. 2004. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev, 9:123–30.

Poole-WilsonPASwedbergKClelandJGComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialLancet200336271312853193

 PubMed Web of Science ®Google Scholar